HER2 Support Group Forums - View Single Post - ImmunoGen reports net loss of $21.9 million in Q4 2013

'lizbeth · 08-02-2013, 01:38 PM

Picking out the really good things from this article since no one is going to get rich off of IMGN stock anytime soon . . .

Roche is assessing Kadcyla in a number of additional indications:

including for first-line treatment of HER2-positive metastatic BC (MARIANNE trial),

for uses in early stage HER2-positive BC (including the KATHERINE trial),

and for the treatment of advanced HER2-positive stomach cancer (GATSBY trial).

The progression-free survival (PFS) endpoint of TH3RESA has been met, and Roche intends to submit these data for presentation at the ESMO annual meeting Sept. 27-Oct. 1, 2013.

Roche expects results from MARIANNE in late 2014 and to apply for first-line treatment of HER2-positive metastatic BC and for treatment of advanced HER2-positive gastric cancer in 2015.

08-02-2013, 01:38 PM	#2
'lizbeth Senior Member Join Date: Apr 2008 Location: Sunny San Diego Posts: 2,214	Re: ImmunoGen reports net loss of $21.9 million in Q4 2013 Picking out the really good things from this article since no one is going to get rich off of IMGN stock anytime soon . . . Roche is assessing Kadcyla in a number of additional indications: including for first-line treatment of HER2-positive metastatic BC (MARIANNE trial), for uses in early stage HER2-positive BC (including the KATHERINE trial), and for the treatment of advanced HER2-positive stomach cancer (GATSBY trial). The progression-free survival (PFS) endpoint of TH3RESA has been met, and Roche intends to submit these data for presentation at the ESMO annual meeting Sept. 27-Oct. 1, 2013. Roche expects results from MARIANNE in late 2014 and to apply for first-line treatment of HER2-positive metastatic BC and for treatment of advanced HER2-positive gastric cancer in 2015.